Heart Failure POC And LOC Devices Market to Grow with a CAGR of 8.25% through 2030

Increasing prevalence of heart failure and the cost-effectiveness of these devices is expected to drive the Global Heart Failure POC And LOC Devices Market growth in the forecast period, 2026-2030.

According to TechSci Research report, “Heart Failure POC And LOC Devices Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Heart Failure POC And LOC Devices Market stood at USD 110.24 million in 2024 and is anticipated to grow with a CAGR of 8.25% in the forecast period, 2025-2030. This can be attributed to growing investment and research. Investment in research and development of POC and LOC devices for heart failure is on the rise. This includes funding from both public and private sectors, which is fostering innovation and improving the quality of these devices. The collaboration between medical device manufacturers, healthcare providers, and tech companies is becoming increasingly common. These partnerships enable the development of cutting-edge solutions and accelerate market growth.

Lab-on-a-chip (LOC) technology has found applications in diagnostics, serving both Point-of-Care (POC) diagnostics and central lab testing. However, as of the current market landscape, only POC tests are commercially available for diagnosing heart failure. This situation, in turn, has opened up promising opportunities for emerging diagnostic developers looking to establish a meaningful presence in this market.

The existence of numerous clinical manifestations of heart failure and often non-specific symptoms has complicated traditional diagnostic methods. As a result, there has been a surge in the development of POC tests, streamlining decision-making for individuals at risk of heart-related conditions. POC tests play a crucial role in identifying cardiac markers and other time-sensitive parameters, effectively addressing the challenges posed by healthcare disparities.

The government entities are taking various measures to mitigate the escalating healthcare costs associated with hospital admissions. For example, the European Commission has provided funding for a project called KardiaTool, which aims to create affordable LOC assays capable of detecting biomarkers from saliva samples to assess the risk of heart failure.

However, the absence of well-defined reimbursement models for POC devices equipped with cassettes or cartridges that conduct multiple tests imposes some limitations on growth. To tackle this challenge, manufacturers are actively devising strategies to secure effective reimbursement for multi-analyte POC tests.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Heart Failure POC And LOC Devices Market”

The Global Heart Failure POC And LOC Devices Market is segmented into test type, technology, end use, regional distribution, and company.

Based on its test type, genomic testing is the fastest-growing segment in the global Heart Failure POC and LOC Devices Market due to its increasing role in personalized medicine, early risk assessment, and targeted therapy selection. The growing understanding of genetic predisposition to heart failure (HF) has fueled demand for genetic biomarkers that enable early detection, prognosis, and tailored treatment strategies. Advances in next-generation sequencing (NGS) and polymerase chain reaction (PCR)-based POC and LOC platforms have made genomic testing faster, more accurate, and accessible at the point of care.

The rising prevalence of heart failure, coupled with increasing awareness of genetic risk factors, has encouraged healthcare providers to integrate genomic testing into routine cardiovascular diagnostics. Government and private sector investments in precision medicine further support the rapid expansion of this segment. The pharmaceutical companies are increasingly leveraging genomic data to develop targeted heart failure therapies, reinforcing the adoption of genomic testing in clinical settings. As technological advancements continue, genomic testing is expected to revolutionize heart failure management by enabling earlier intervention, improved patient stratification, and personalized treatment approaches. This strong potential for clinical impact and market expansion makes genomic testing the fastest-growing category in the Heart Failure POC and LOC Devices Market.

Based on region, Asia-Pacific region is the fastest-growing in the global Heart Failure POC and LOC Devices Market due to its rising cardiovascular disease burden, growing aging population, and increasing healthcare investments. The high prevalence of heart failure (HF) in countries like China, India, and Japan, driven by lifestyle changes and higher diabetes and hypertension rates, fuels demand for rapid and accessible diagnostics. Expanding government initiatives, improved healthcare infrastructure, and rising adoption of point-of-care (POC) and lab-on-a-chip (LOC) devices enhance market growth. Advancements in telemedicine, growing awareness, and affordability of portable diagnostic solutions further accelerate adoption in hospitals, clinics, and homecare settings across the region.

Major companies operating in Global Heart Failure POC And LOC Devices Market are:

·         Abbott Laboratories Inc

·         Siemens Healthineers AG

·         Danaher Corp

·         Instrumentation Laboratory Co

·         F Hoffmann-La Roche AG

·         bioMérieux S.A.

·         Abaxis Inc

·         Quidel Corp

·         Jant Pharmacal Corp

·         Trinity Biotech plc

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The Global Heart Failure POC and LOC Devices Market is evolving rapidly, with the emerging trends promising a future where heart failure management is more personalized, efficient, and patient-centered. Innovations in AI, remote monitoring, wearables, and data analytics are at the forefront of this transformation. As these trends continue to shape the market, they hold the potential to improve patient outcomes, reduce healthcare costs, and enhance the quality of life for individuals living with heart failure. Staying attuned to these trends is vital for all stakeholders in the healthcare industry as they navigate the ever-changing landscape of heart failure management” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Heart Failure POC And LOC Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Proteomic testing, Metabolomic testing, Genomic testing), By Technology (Microfluidics, Array-based systems, Others), By End Use (Clinics, Hospitals, Home, Assisted living healthcare facilities, Laboratory, Others), By Region & Competition 2020-2030F”, has evaluated the future growth potential of Global Heart Failure POC And LOC Devices Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Heart Failure POC And LOC Devices Market.

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               

Website: www.techsciresearch.com